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ABSTRACT
Objective To determine whether assessment tools for 
non- randomised studies (NRS) address critical elements 
that influence the validity of NRS findings for comparative 
safety and effectiveness of medications.
Design Systematic review and Delphi survey.
Data sources We searched PubMed, Embase, Google, 
bibliographies of reviews and websites of influential 
organisations from inception to November 2019. In 
parallel, we conducted a Delphi survey among the 
International Society for Pharmacoepidemiology 
Comparative Effectiveness Research Special Interest 
Group to identify key methodological challenges for NRS 
of medications. We created a framework consisting of 
the reported methodological challenges to evaluate the 
selected NRS tools.
Study selection Checklists or scales assessing NRS.
Data extraction Two reviewers extracted general 
information and content data related to the prespecified 
framework.
Results Of 44 tools reviewed, 48% (n=21) assess 
multiple NRS designs, while other tools specifically 
addressed case–control (n=12, 27%) or cohort studies 
(n=11, 25%) only. Response rate to the Delphi survey 
was 73% (35 out of 48 content experts), and a consensus 
was reached in only two rounds. Most tools evaluated 
methods for selecting study participants (n=43, 98%), 
although only one addressed selection bias due to 
depletion of susceptibles (2%). Many tools addressed the 
measurement of exposure and outcome (n=40, 91%), and 
measurement and control for confounders (n=40, 91%). 
Most tools have at least one item/question on design- 
specific sources of bias (n=40, 91%), but only a few 
investigate reverse causation (n=8, 18%), detection bias 
(n=4, 9%), time- related bias (n=3, 7%), lack of new- user 
design (n=2, 5%) or active comparator design (n=0). Few 
tools address the appropriateness of statistical analyses 
(n=15, 34%), methods for assessing internal (n=15, 34%) 
or external validity (n=11, 25%) and statistical uncertainty 
in the findings (n=21, 48%). None of the reviewed 
tools investigated all the methodological domains and 
subdomains.
Conclusions The acknowledgement of major design- 
specific sources of bias (eg, lack of new- user design, 
lack of active comparator design, time- related bias, 
depletion of susceptibles, reverse causation) and statistical 
assessment of internal and external validity is currently not 
sufficiently addressed in most of the existing tools. These 
critical elements should be integrated to systematically 
investigate the validity of NRS on comparative safety and 
effectiveness of medications.
Systematic review protocol and registration https:// 
osf. io/ es65q.
INTRODUCTION
There are high expectations that real- world 
data (RWD) and resultant real- world evidence 
(RWE) will become a key source of informa-
tion for the development process of pharma-
cological or biological therapies.1–3 The 21st 
Century Cures Act and the sixth Prescription 
Drug User Fee Act required the Food and 
Drug Administration (FDA) to explore the 
use of RWE and, consequently, well- designed 
and conducted non- randomised studies 
Strengths and limitations of this study
 ► This is the first systematic review to investigate 
whether existing tools adequately assess the validity 
of non- randomised studies evaluating the compara-
tive safety and effectiveness of medications.
 ► Assessment tools were identified by searching 
through multiple sources: relevant databases, grey 
literature, websites of authoritative organisations, 
bibliographies of previous systematic reviews and 
experts’ suggestions.
 ► The prepiloted framework adopted to evaluate the 
completeness of the tools included all the main 
methodological challenges suggested by an inter-
disciplinary (academia, industry and government 
agencies) and international team of experts in the 
field of pharmacoepidemiology and healthcare out-
comes research.
 ► Tools not published in English or that could not be 
retrieved were omitted from this systematic review.
 ► The search for tools in the grey literature might not 
be comprehensive since it was performed through 
only one browser.
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(NRS) for expediting drug approvals.4 5 Similarly, one 
of the goals of the European Medicines Agency (EMA) 
Adaptive Pathways Initiative is to supplement clinical trial 
data with RWD and to eventually produce RWE as part of 
the approval process of new medications or indications.6
However, the growing demand for RWD has raised 
concerns about the reliability of NRS to generate RWE. 
Due to the inherent limitations of observational analyses, 
the validity of NRS depends largely on the implemen-
tation of complex design and analytic methodologies. 
In recent reports, both FDA and EMA emphasised the 
need to plan and execute NRS following standards that 
can ensure validity and reproducibility of RWE.7 8 Tools 
that assess the validity of NRS can be useful instruments 
for both researchers (eg, for authors and reviewers to 
prevent publication of poor quality pharmacoepidemio-
logical research) and other stakeholders who are involved 
in clinical, managemental or economic decision making 
(eg, to correctly inform guidelines and clinicians or to 
guide resource allocation).
An analysis on the capability of existing tools to assess 
the validity of NRS of comparative safety and effectiveness 
of medications is currently lacking. Previously published 
systematic reviews on assessment tools for NRS were 
mostly descriptive and did not provide a critical evalua-
tion of the tools content,9–13 investigated only a specific 
type of bias14 or focused only on safety outcomes.15 
Therefore, we conducted a systematic review to assess the 
content of eligible tools for NRS of medications. There 
is no agreement on an assessment framework for NRS of 
pharmacological interventions. Thus, we performed a 
Delphi survey among international experts in the field of 
pharmacoepidemiology and health outcome research in order to 
build consensus for the methodological challenges that 
may threaten the validity of NRS of medications and that 
should be evaluated by assessment NRS tools.
The main objective of this study was to determine 
whether the retrieved NRS tools sufficiently address the 
main methodological challenges recommended by the 
experts. This study is part of a research project to develop 
a framework for the synthesis of NRS and randomised 
controlled trials (RCTs),16 led by the Comparative Effec-
tiveness Research Special Interest Group (CER SIG) of 
the International Society for Pharmacoepidemiology 
(ISPE).
METHODS
The systematic review was conducted according to the 
Preferred Reporting Items for Systematic Reviews and 
Meta- analyses statement.17 Systematic review protocol 
and registration are available at https:// osf. io/ es65q.
Systematic search and eligibility criteria
We searched PubMed and Embase from inception to 
November 2019 to identify existing tools that inves-
tigated the validity of NRS, specifically case–control 
and cohort design studies. We excluded guidelines or 
manuals, tools to review study protocols, tools targeting 
NRS of non- pharmacological interventions (eg, surgery) 
or assessing only one or a few specific types of bias, and 
tools not available in English language. In parallel, we 
searched the same electronic databases for systematic 
reviews of assessment tools of NRS. We then extracted 
the references of the tools included in the systematic 
reviews retrieved. We also performed a general search 
through Google for grey literature and reviewed any 
additional information from initiatives, programmes 
or organisations. Full details on the search strategy are 
reported in the supplement (online supplemental tables 
S1 and S2). Three reviewers (ED, GS and LV) inde-
pendently removed duplicates and reviewed titles and 
abstracts of peer- reviewed publications or documents 
from the grey literature to select eligible tools. Discrep-
ancies were resolved by consensus.
Delphi survey and prespecified framework
Concurrently, we performed a Delphi survey18 to reach a 
consensus among content experts about the main meth-
odological challenges (domains) that may threaten the 
validity of NRS on comparative safety and effectiveness 
of medications. The survey is available in the online 
supplemental 2. The panel of experts involved members 
of the SIG for CER of the ISPE. Detailed information on 
the Delphi methods and results is reported in the online 
supplemental 1.
Domains and subdomains indicated by the Delphi 
respondents as major elements that can impact the 
validity of NRS of medications were used to develop and 
pilot a framework to evaluate the identified NRS tools. All 
domains were considered equally important. A glossary of 
terms used in the framework is reported in table 1.
Data extraction
Two reviewers (ED and LV) independently extracted general 
information of the identified tools (first author or name of 
the tool, year of publication or online availability of the most 
updated version, type of tool, scope of the tool, NRS designs 
evaluated and number of items) and content data related 
to the prespecified domains of the framework. Discrepan-
cies were resolved by consensus. We categorised the tools as 
checklists, defined as itemised instruments (including ques-
tionnaires) developed to identify the presence or absence of 
critical elements, or rating scales, defined as itemised instru-
ments aimed to identify the performance of a study at each 
critical element described in the tool, using a qualitative or 
quantitative scale.
Data synthesis
General characteristics of the identified tools were 
summarised with means and SD, for continuous vari-
ables, and relative frequencies, for categorical variables. 
The findings from the Delphi survey and the proportion 
of tools assessing the prespecified elements of the frame-
work were reported in terms of relative frequencies.
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Of 44 tools that met our eligibility criteria,19–52 20 (45%) 
were identified through the database search of peer- 
reviewed literature and 24 (55%) through the general 
online search and other sources (online supplemental 
figure S1 and table S3). Characteristics of the tools are 
shown in tables 2 and 3. The number of items across all 
tools ranged from 5 to 54, with a median of 13.5 (IQR 
10.3–22). Only three tools were designed to specifically 
address studies on the comparative safety and effective-
ness of pharmacological interventions: one published 
in 1994 by Cho and Bero,46 the The Good ReseArch 
for Comparative Effectiveness (GRACE) checklist and 
the International Society for Pharmacoeconomics 
and Outcomes Research – Academy of Managed Care 
Pharmacy – National Pharmaceutical Council (ISPOR- 
AMCP- NPC) tool, both published in 2014.25 26
Tool formats and scopes
Most of the tools were checklists (n=35, 80%), and 13 
checklists included a final section to elaborate a summary 
judgement of the study appraisal (37%). The remaining 
tools were scales (n=9, 20%), and six of them provided a 
section for a summary judgement (67%).
Thirty- five tools (80%) were designed as critical appraisal 
tools for different scopes (eg, assessing the quality of NRS 
included in a systematic review, screening eligible NRS to 
Table 1 Glossary of terms
Term Definition
Active comparator design A study design that compares the effect of the drug of interest with another drug used in clinical 
practice instead of non- use.
Adjustment for causal 
intermediaries
Adjustment for an intermediate variable (or a descending proxy for an intermediate variable) on a 
causal path from exposure to outcome.
Case–control design A study design in which cases (patients with outcomes) are identified and compared with controls 
(patients without outcomes) with respect to the exposure of interest.
Cohort design A study design in which a group of patients (a cohort) is identified and followed to ascertain the 
occurrence of an outcome.
Confounding A mixing of effects that arises when patients with different baseline risks are compared; the 
resulting effect measure is a mix of drug effects and risk factor effects.
Depletion of susceptibles Selection bias that occurs when the initiation of exposure to a drug is associated with an early 
increased incidence rate of the study outcome, followed by a decreased incidence rate with longer 
duration of exposure (eg, users of new drugs are compared with users of older drugs).
Detection or surveillance 
bias
Bias that occurs when the degree of outcome surveillance (or an associated symptom) is related to 
exposure and is differential among the exposure groups.
Immortal time bias Time- related bias that derives from including a period of follow- up during which, by design, 
outcomes cannot occur.
Time- window bias Time- related bias, in the context of a case–control study nested in a cohort, that derives from the 
use of time- windows of different lengths between cases and controls to define time- dependent 
exposures.
Incorrect outcome model 
specification
Misspecification of a statistical model that leads to biased outcome results. Common causes are 
omission of a relevant variable, inclusion of an unnecessary variable, adopting the wrong functional 
form, incorrect specification of the error term, uncertainty about what the true model is and 
reciprocal causation.
Loss to follow- up bias Bias that occurs when there is difference in retention during the follow- up period after enrolment 
that are related to exposure status and outcome.




Bias generated by differences in the timing of selection of comparator group(s) within a study 
influence exposures and outcomes resulting in biased estimates.
Reverse causation (or 
reverse causality)
Bias due to direction of cause and effect contrary to a common presumption, or a two- way causal 
relationship between exposure and outcome.
Recall bias Bias that occurs when participants do not remember previous events or experiences accurately or 
omit details (not for claims- based studies).
Selection bias Bias that occurs when selection of participants or follow- up time is related to both intervention 
and outcome (eg, prevalent users of a drug are compared with non- users or incident users). Our 
framework has a separate subdomain that refers to selection bias due to lack of generalisability, 
applicability or transferability to patients who were excluded from the study.
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include in systematic reviews to support clinical guidelines, 
supporting peer- review processes or, more general, allowing 
readers to interpret NRS results critically). Four tools (9%) 
were developed to assess the quality of reporting and were 
mainly intended for researchers. Five other tools (11%) 
combined elements of both critical appraisal and quality 
Table 2 Individual characteristics of the tools included in the systematic review
Tool identified* Year Type of tool Scope of the tool
Study design 
evaluated tems
RELEVANT 2019 Checklist Critical appraisal and reporting NRS 21
RAMboMAN - GATE- EPIQ 2019 Rating scale+summary judgement Critical appraisal Coh (+RCTs), CC Coh (+RCTs) 21, CC 18
MMAT 2018 Checklist Critical appraisal NRS 5
CASP 2018 Checklist Critical appraisal Coh, CC Coh 12, CC 11
SURE 2018 Checklist+summary judgement Critical appraisal Coh, CC Coh 13, CC 11
JBI 2017 Checklist+summary judgement Critical appraisal Coh, CC Coh 11, CC 10
ROBINS- I 2016 Checklist+summary judgement Critical appraisal NRS 34 (+8 optional 
question)
ISPOR- AMCP- NPC† 2014 Checklist+summary judgement Critical appraisal Coh CC 32
GRACE† 2014 Checklist+summary judgement Critical appraisal Coh CC 11
NIH–NHLBI 2014 Checklist+summary judgement Critical appraisal Coh (+CSS), CC Coh (+CSS) 14, CC 12
HEBW 2014 Checklist+summary judgement Critical appraisal Coh 18
RoBANS 2013 Rating scale Critical appraisal NRS 6
RTI- Item Bank 2013 Checklist Critical appraisal NRS 13
Newcastle- Ottawa 2013 Rating scale +summary judgement Critical appraisal Coh, CC Coh 8, CC 8
SIGN - V.3.0 2012 Checklist+summary judgement Critical appraisal Coh, CC Coh 14, CC 11
Montreal 2011 Checklist Critical appraisal Coh CC (+RCTs) 10
EPHPP 2011 Rating scale Critical appraisal Coh CC (+RCTs) 17
STROBE – V.4 2007 Checklist Reporting Coh, CC Coh 22, CC 22
TREND 2004 Checklist Reporting NRS 22
Margetts 2002 Checklist Reporting Coh CC 11
Zaza 2000 Checklist Critical appraisal Coh CC 15
Downs- Black 1998 Rating scale Critical appraisal and reporting Coh CC (+RCTs) 27
Elwood 1998 Checklist Critical appraisal Coh CC (+RCTs) 20
Hadorn 1996 Checklist Critical appraisal Coh (+RCTs) 7
London 1996 Checklist Critical appraisal Coh CC 33
Avis 1994 Rating scale+summary judgement Critical appraisal and reporting Coh CC (+RCTs) 24
Durant 1994 Checklist Critical appraisal CC 23
Levine 1994 Checklist Critical appraisal Coh CC (+RCTs) 10
Gyorkos 1994 Checklist Critical appraisal Coh, CC Coh 6, CC 5
Cho† 1994 Rating scale+summary judgement Critical appraisal NRS (+RCTs) 24
COEH 1991 Checklist Critical appraisal NRS 54
Fowkes- Fulton 1991 Checklist+summary judgement Critical appraisal and reporting NRS (+RCTs) 6
Lichtenstein 1987 Checklist Critical appraisal CC 20
Gardner 1986 Checklist Critical appraisal NRS 12
Horwitz 1979 Checklist Critical appraisal and reporting CC 12
Nine tools from our bibliographic search provided two separate instruments to assess cohort or case–control studies. Thus, the overall number of included records 
is 35, while the number of included assessment tools is 44.
*Tool name or first author name, if the tool does not have an assigned name, and it was published in peer- review journals.
†Tool developed to assess NRS on the comparative safety and effectiveness of medications.
CASP, The Critical Appraisals Skills Programme; CC, case–control study; COEH, Centre for Occupational and Environmental Health of The University of Manchester; 
Coh, cohort study; CSS, cross- sectional study; EPHPP, Effective Public Health Practice Project Quality Assessment Tool; GRACE, The Good ReseArch for 
Comparative Effectiveness; HEBW, Health Evidence Bulletins Wales; ISPOR- AMCP- NPC, International Society for Pharmacoeconomics and Outcomes Research 
– Academy of Managed Care Pharmacy – National Pharmaceutical Council; JBI, The Joanna Briggs Institute; MMAT, Mixed Methods Appraisal Tool; NIH–NHLBI, 
The National Institute of Health - The National Heart, Lung, and Blood Institute; NRS, non- randomised studies; RAMboMAN, GATE- EPIQ, Recruitment Allocation 
Maintenance blind objective Measurements Analyses, Graphic Approach To Epidemiology – Effective Practice, Informatics and Quality Improvement; RCTs, 
randomised controlled trials; RELEVANT, The REal Life EVidence AssessmeNt Tool; RoBANS, Risk of Bias Assessment tool for Non- randomized Studies; ROBINS- I, 
Risk Of Bias In Non- randomized Studies of Interventions; RTI- Item Bank, Research Triangle Institute Item Bank; SIGN, The Scottish Intercollegiate Guidelines 
Network; STROBE, STrengthening the Reporting of OBservational studies in Epidemiology; SURE, Specialist Unit for Review Evidence; TREND, Transparent 
Reporting of Evaluations with Non- randomized designs.
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reporting and were for a more general audience (both 
researchers and readers) (tables 2 and 3).
Study designs addressed
Twenty- one tools (48%) were developed to assess multiple 
NRS designs (11 targeted cohort and case–control studies 
and 10 others addressed also other NRS designs or did not 
specify them). Other tools specifically addressed case–control 
(n=12, 27%) or cohort studies (n=11, 25%). Ten tools (23%) 
were designed to assess also RCTs.
Tool elements
The response rate of the Delphi survey was 73% (35 respon-
dents out of 48 members). Detailed results are reported in 
the online supplemental figure S2. Domains and subdo-
mains indicated by the respondents as major elements that 
can impact the validity of NRS of medications are reported in 
the first column of table 4.
Methods for selecting participants
Nearly all tools assessed methods for selecting study partic-
ipants to correct selection bias (n=43, 98%). Specifically, 
almost half of the tools included items related to sampling 
strategies (n=19, 43%), the definition of inclusion and exclu-
sion criteria (n=27, 61%) and the generalisability of partic-
ipants (ie, attempts to achieve a sample of participants that 
represents the target population) (n=21, 48%), while only 
one tool addressed the depletion of susceptibles (n=1, 2%) 
(table 4 and online supplemental figure S3).
Measurement of exposure, outcomes, covariates and follow-up
Forty- two tools (95%) had at least one item assessing the 
definition and measurement of exposure, outcome, covari-
ates and follow- up. Assessment of exposure and outcome was 
widely reported by the tools (n=40, 91%), while definition 
and measurement of covariates (n=12, 27%) or follow- up 
(n=17, 39%) were less often addressed (with the exception 
for tools addressing follow- up in cohort studies only, n=9, 
82%) (table 4 and online supplemental figure S4).
Design-specific sources of bias
Design- specific sources of bias (excluding selection bias which 
was investigated in ‘Methods for selecting participants’) were 
assessed by 91% of the tools (n=40) and generally included 
loss to follow- up bias (n=22, 50%), observer or interviewer 
bias (n=11, 25%), reverse causation bias (n=8, 18%), recall 
bias (n=6, 14%) and non- contemporaneous comparator bias 
(n=6, 14%). A few or no tools assessed detection or surveil-
lance bias (n=4, 9%), time- related bias, such as immortal 
person- time bias or time- window bias (n=3, 7%), and biases 
due to lack of new- user design (n=2, 5%) or active compar-
ator design (n=0). Other tools reported only a general item/
question on the risk of bias (n=9, 20%), without any refer-
ence to a specific type of bias.
Tools specifically for cohort studies addressed more 
frequently loss to follow- up (n=9, 82%) and reverse causation 
biases (n=5, 45%) compared with the other tools, while 
tools for case–control studies addressed mostly recall (n=4, 










Publication year, n (%)
  1979–1989 3 (7) 0 (0) 2 (17) 1 (5)
  1990–1999 12 (27) 2 (18) 2 (17) 8 (38)
  2000–2009 5 (11) 1 (9) 1 (8) 3 (14)
  2010–2019 24 (55) 8 (73) 7 (58) 9 (43)
Type of tool, n (%)
  Checklist 22 (50) 4 (36) 6 (50) 12 (57)
  Checklist+summary judgement 13 (30) 5 (45) 4 (33) 4 (19)
  Rating scale 3 (7) 0 (0) 0 (0) 3 (14)
  Rating scale+summary judgement 6 (14) 2 (18) 2 (16) 2 (9)
Scope of the tool, n (%)
  Critical appraisal 35 (80) 9 (81) 10 (83) 16 (76)
  Reporting 4 (9) 2 (18) 1 (8) 1 (5)
  Critical appraisal and reporting 5 (11) 0 (0) 1 (8) 4 (19)
Tools designed for CER, n (%) 3 (7) 0 (0) 0 (0) 3 (14)
Number of items, median (IQR) 13 (10.3–21.8) 13 (9.5–16) 11.5 (10.8–18.5) 17 (11–24)
*Two tools evaluated both cohort and RCTs together; one tool evaluated both cohort and cross- sectional studies together.
†NRS tools refer to a single tool built to evaluate both cohort and case–control studies or a tool built to evaluate additional NRS (eg, cross- 
sectional studies and before–after studies) together with cohort and case–control studies. Eight NRS tools included also the evaluation of 
RCTs.
CER, Comparative Effectiveness research; NRS, non- randomised studies; RCTs, randomised controlled trials.
 on M









pen: first published as 10.1136/bm





6 D'Andrea E, et al. BMJ Open 2021;11:e043961. doi:10.1136/bmjopen-2020-043961
Open access 
33%) and observer biases (n=3, 25%). Tools for multiple 
NRS covered commonly loss to follow- up (n=12, 57%) and 
interviewer or observer biases (n=7, 35%) (table 4 and online 
supplemental figure S5).
Confounding
Forty tools (91%) included at least one item or question 
related to confounding. Specifically, 26 tools (59%) searched 
whether study design was planned in a way to minimise 










1. Methods for selecting participants, n (%) 11 (100) 12 (100) 20 (95) 43 (98)
  Sampling strategies to correct selection bias 4 (36) 6 (50) 9 (42) 19 (43)
  Inclusion and exclusion criteria of target population 6 (55) 8 (67) 13 (61) 27 (61)
  Depletion of susceptibles 1 (9) 0 (0) 0 (0) 1 (2)
  External validity of target population 6 (55) 6 (50) 9 (43) 21 (48)
  Others‡ 11 (100) 12 (100) 18 (86) 41 (93)
2. Measurement of exposure, outcomes, covariates and follow- up, n (%)§ 11 (100) 12 (100) 19 (90) 42 (95)
  Measurement of exposure§ 11 (100) 11 (92) 18 (81) 40 (91)
  Measurement of outcomes§ 11 (100) 11 (92) 18 (81) 40 (91)
  Measurement of covariates 4 (36) 4 (33) 4 (19) 12 (27)
  Measurement of follow- up 9 (82) 3 (25) 5 (24) 17 (39)
3. Design- specific sources of bias, n (%) 11 (100) 10 (83) 19 (90) 40 (91)
  New- user design 0 (0) 0 (0) 2 (10) 2 (5)
  Active comparator design 0 (0) 0 (0) 0 (0) 0 (0)
  Immortal time bias or time- window bias 0 (0) 0 (0) 3 (14) 3 (7)
  Detection or surveillance bias 1 (9) 2 (17) 1 (5) 4 (9)
  Loss to follow- up bias 9 (82) 1 (8) 12 (57) 22 (50)
  Non- contemporaneous comparator bias 0 (0) 1 (8) 5 (24) 6 (14)
  Reverse causation 5 (45) 1 (8) 2 (10) 8 (18)
  Recall bias¶ 1 (9) 4 (33) 1 (5) 6 (14)
  Interviewer or observer bias¶ 1 (9) 3 (25) 7 (35) 11 (25)
  Ascertainment bias¶ 0 (0) 1 (8) 1 (5) 2 (5)
  General item/question on bias¶ 3 (27) 3 (25) 3 (14) 9 (20)
  Other biases** 0 (0) 2 (17) 5 (24) 7 (16)
4. Confounding, n (%) 11 (100) 11 (92) 18 (86) 40 (91)
  Study design used to minimise confounding 6 (55) 7 (58) 13 (62) 26 (59)
  Confounders measured and included in statistical analyses 10 (91) 10 (83) 18 (86) 38 (86)
  Potential unmeasured confounding addressed in the analysis (eg, proxy 
analysis and IV analysis)
1 (9) 1 (8) 3 (14) 5 (11)
5. Lack of appropriateness of statistical analyses (with specific mention of 
overadjustment and/or incorrect outcome model specification), n (%)
2 (18) 3 (25) 10 (48) 15 (34)
6. Methods for assessing statistical uncertainty in the findings (eg, CIs 
reported for each analysis), n (%)
7 (64) 6 (50) 8 (38) 21 (48)
7. Methods for assessing internal validity (eg, sensitivity analysis addressing 
potential confounding, measurement errors or other biases), n (%)
3 (27) 3 (25) 9 (43) 15 (34)
8. Methods for assessing external validity (eg, post hoc subgroup analysis 
and comparison with other populations), n (%)
4 (36) 3 (25) 4 (19) 11 (25)
*Two tools evaluated both cohort and RCTs together; one tool evaluated both cohort and cross- sectional studies together.
†NRS tools refer to a single tool built to evaluate both cohort and case–control studies or a tool built to evaluate additional NRS (eg, cross- sectional 
studies and before–after studies) together with cohort and case–control studies. Eight NRS tools included also the evaluation of RCTs.
‡'Others’ refers to items not included in our evaluation framework but included in the reviewed tools to investigate selection bias (eg, population 
characteristics sufficiently described to determine the applicability of the research question, sample size justification and power description, and 
ethical considerations).
§Items or questions on exposure misclassification and/or outcome misclassification are counted in this domain and relative subdomains.
¶Design- specific biases not included in the evaluation framework but addressed by the reviewed tools.
**Other design- specific biases not included in the evaluation framework but addressed by a few tools (eg, bias due to missing data, patients' 
blinding, different length of follow- up between groups, Berkson’s bias and protopathic bias).
IV, instrumental variable; NRS, non- randomised studies; RCTs, randomised controlled trials.
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confounding, 38 (86%) whether confounders were measured 
and included in the analyses and only five whether potential 
unmeasured confounding was assessed in the sensitivity anal-
yses (11%) (table 4 and online supplemental figure S6).
Appropriateness of statistical analyses, external and internal 
validity
One- third of the tools (n=14, 32%) assessed the appropri-
ateness of statistical analyses, although most of them did not 
explicitly mention overadjustment of causal intermediates 
and/or incorrect outcome model specification. Almost half 
(n=21, 48%) included methods for measuring uncertainty 
in the findings. Few tools addressed methods for evalu-
ating internal (n=15, 34%) or external validity (n=11, 25%) 
(table 4 and online supplemental figure S7 in the online 
supplement).
These results were mostly consistent across the three 
different types of design addressed, cohort only, case–
control only and multiple NRS, except for the assess-
ment of follow- up (domain 2) and several design- specific 
sources of biases (domain 3) already mentioned above 
(table 4). None of the reviewed tools covered all the main 
domains and subdomains as identified by the CER SIG 
and listed in table 4.
Results for each selected tool on the proportions of 
items/questions that investigate the prespecified domains 
are shown in the online supplemental figures S8–S11.
DISCUSSION
In this systematic review, we identified assessment tools 
evaluating the validity of NRS on comparative safety and 
effectiveness of medications. Of 44 tools included, only 
three were specifically designed to assess NRS of pharma-
cological interventions.25 26 46
Main findings
Overall, we found that existing tools assessed most of the 
methodological challenges identified by the domains of 
the CER SIG framework, but critical elements were often 
insufficiently addressed. For example, although many 
tools assessed the risk of selection bias, only half of them 
explicitly investigated sampling strategies and consid-
ered a prespecification of inclusion/exclusion criteria. 
Even more surprising was that only one tool explored the 
potential for selection bias due to depletion of patients 
that are susceptible to the outcome. This cohort- based 
phenomenon can occur when new users of a medication 
are depleted of all susceptible subjects to the outcome, 
documenting an increased incidence rate of the outcome 
in an early stage, followed by a decreased rate with a 
longer duration of exposure.53 Depletion of susceptibles 
is an important source of bias to account for when evalu-
ating effects of new medications in incident users and can 
significantly undermine the validity of the results.53
Similarly, many tools investigated misclassification or 
information bias of exposure and outcome. However, only 
about one- third assessed definition and measurement of 
covariates, and less than one- fourth of the case–control 
and multiple NRS designs tools assessed information on 
follow- up definition. Again, these are common causes of 
bias and should be integrated in tools that investigate the 
validity of NRS.
Design- specific sources of bias was a critical domain. 
Although overall 91% of the tools had at least one item/
question investigating biases due to an inappropriate 
study design, only Risk Of Bias In Non- randomized 
Studies of Interventions (ROBINS- I) and the GRACE 
checklist addressed bias due to lack of new- user design 
and time- related bias (ie, immortal person- time bias or 
time- window bias), while no tools investigated bias due 
to lack of active comparator design. Since these biases 
can independently lead to major methodological flaws 
(defined as elements that by themselves can significantly 
compromise the validity of the results), their assessment 
must be included in appraisal tools for NRS of pharma-
cological interventions. For example, recent evidence on 
NRS of glucose- lowering medications reported that only 
one- fourth of the studies adopted a new- user design and 
less than half used an active comparator.54 In the same 
example, potential for time- related bias was detected 
in more than two- third of the studies.54 Integrating 
the evaluation of these major methodological flaws in 
existing tools and recommending the use of these tools 
before publication can increase awareness in the clinical 
research community with respect to main design- specific 
biases. This can ultimately decrease the amount of NRS 
with invalid findings on the safety or effectiveness of 
medications.
A high percentage of tools evaluated whether 
confounders were appropriately measured, controlled 
for in the analysis and considered in the study design. 
However, very few tools included at least one item/ques-
tion on whether potential unmeasured confounding 
had been considered in the analysis or interpretation of 
findings.
One- third of the tools checked the appropriateness of 
statistical analyses, but most omitted specific reference 
to common flaws such as overadjustment or incorrect 
outcome model specification. Similarly, only one- third of 
the tools assessed internal validity (eg, through sensitivity 
analysis to address potential confounding, measurement 
errors or other biases), and only one- fourth assessed 
external validity (eg, post hoc subgroup analysis and 
comparison with other populations).
Implications for practice and research
While recently published tools such as The Crit-
ical Appraisals Skills Programme checklist,21 ISPOR- 
AMCP- NPC,25 Recruitment Allocation Maintenance 
blind objective Measurements Analyses,19 GRACE26 
and ROBINS- I24 are among the most complete tools, 
addressing several of the critical elements underlined by 
the ISPE CER SIG, they all had limitations in the acknowl-
edgement of two or more major methodological chal-
lenges (eg, selection bias for depletion of susceptibles, 
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immortal- time bias or window- time bias, lack of new- 
user design, lack of active comparator design, reverse 
causation bias and adjustment for causal intermedi-
aries). Assessment tools can be powerful instruments for 
researchers, authors, reviewers of scientific journals or 
readers, helping to identify the main limitations of a study 
and to correctly interpret the results, to acknowledge 
major methodological flaws and, ultimately, to prevent 
publication of studies with invalid findings.
Furthermore, other decision makers, such as clinicians, 
guideline developers and payers or investors, can benefit 
from instruments that help to ensure the validity of NRS 
findings. RCTs can be an insufficient source of evidence 
for decisions on pharmaceutical interventions.55 56 Despite 
well- designed and adequately powered RCTs being consid-
ered the ‘gold standard’ of the clinical research paradigm, 
they can often be too time intensive and money inten-
sive. Trials are often relatively small, focus on short- term 
efficacy and safety in a controlled clinical environment, 
using surrogate outcomes or under- representing high- risk 
populations that can be most likely the target on the new 
medications in the real- world setting.55 56 Trials might also 
not record treatments taken outside the study protocol.47 
Additionally, patients volunteered to participate in a 
trial are usually very motivated and so more adherent 
to therapy compared with the real- world population.56 
NRS based on RWD can help to address these issues and 
could be supplement the evidence from RCTs to provide 
a more complete picture on the effectiveness of pharma-
ceutical interventions in less controlled environments. 
NRSs have the advantages to investigate large- scale popu-
lations, high- risk subpopulations, rare exposures, diseases 
or outcome, and long- term outcomes or other delayed 
health effects at low costs and rapidly.55 56 Moreover, since 
RWD are often collected for intents unrelated to research 
objectives (mainly administrative), biases such as recall 
bias, interviewer bias, non- response bias and bias for loss 
to follow- up are reduced or eliminated.55 Thus, since 
RWE derived by NRS contribute significantly to generate 
evidence of comparative effectiveness research of medi-
cations, our synthesis can help numerous stakeholders to 
evaluate whether the NRS considered are valid enough to 
guide decision making.
Although checklists have been previously suggested 
for reviewing the risk of bias of general NRS,57 we cannot 
strongly recommend a specific tool for NRS on compara-
tive analyses of medications. As already mentioned, items 
or questions that address all those methodological flaws 
must be integrated in the existing tools. Based on our 
findings, most recent and comprehensive tools such as 
ROBINS- I24 and GRACE26 assessed a higher number of 
major methodological elements and could therefore be 
prioritised in this endeavour.
Strengths and limitations
To our knowledge, this is the first systematic review that 
investigated whether existing tools adequately assess the 
validity of cohort and case–control studies evaluating 
the comparative safety and effectiveness of medications. 
Previously published systematic reviews on assessment 
tools for NRS were not specifically focused on pharma-
cological interventions,9 10 included randomised study 
designs11–13 or investigated only a specific type of bias.14 
One systematic review of NRS tools for medications 
focused only on safety outcomes, and it is now outdated 
since published in 2012.15 Our systematic review has 
multiple strengths: authors reviewed the results of the 
searches independently following a predefined protocol; 
the framework for data extraction was developed based 
on inputs of worldwide experts in the field of pharma-
coepidemiology and healthcare outcomes research 
coming from different backgrounds (academia, industry 
and governmental agency) and different countries, and 
it included the most updated versions of the identified 
tools. This review also has limitations. Search for tools in 
the grey literature might not be comprehensive since it 
was performed through only one browser. The search was 
also restricted to tools published in English and excluded 
identified tools that could not be retrieved.
CONCLUSION
In this systematic review, we found that available tools for 
NRS assessment failed to provide a comprehensive assess-
ment of major methodological aspects that can affect the 
validity of NRS on the comparative safety and effective-
ness of medications. Specifically, major aspects such as 
lack of new- user design, active comparator design, time- 
related bias (ie, immortal time bias and time- window 
bias) and statistical assessment of internal validity remain 
poorly covered. Including these critical elements into 
existing tools may provide a more accurate instrument 
to evaluate NRS of pharmacological interventions and 
increase awareness in the clinical research community 
about major addressable flaws in pharmacoepidemiology. 
This may improve the validity of NRS on the comparative 
safety and effectiveness of medications and reduce the 
publication of studies with unreliable findings.
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